<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604224</url>
  </required_header>
  <id_info>
    <org_study_id>CR108507</org_study_id>
    <secondary_id>28431754DIA4030</secondary_id>
    <nct_id>NCT03604224</nct_id>
  </id_info>
  <brief_title>A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI&gt;25 kg/m^2, in Real World Clinical Setting</brief_title>
  <official_title>Retrospective Observational Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Patients With BMI&gt;25 kg/m^2, in Real World Clinical Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Private Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Private Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe clinical effectiveness of canagliflozin by mean
      haemoglobin A1c (HbA1C) and body weight changes from baseline to 12 weeks in Indian type 2
      diabetes participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>Change in mean HbA1c from baseline to 12 weeks will be determined. HbA1c refers to glycated haemoglobin (A1c), which identifies average plasma glucose concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Weight</measure>
    <time_frame>Baseline up to 12 weeks</time_frame>
    <description>Change in mean body weight from baseline to 12 weeks will be determined.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">178</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Canagliflozin Containing Treatment Regimens</arm_group_label>
    <description>No intervention will be administered as a part of this study. Participants with type 2 diabetes mellitus (T2DM) who were initiated on canagliflozin 300 milligram (mg) treatment 12 weeks back and meeting the inclusion criteria will be observed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin 300 mg</intervention_name>
    <description>Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.</description>
    <arm_group_label>Canagliflozin Containing Treatment Regimens</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include Indian type 2 diabetes mellitus (T2DM) participants with body mass
        index (BMI) greater than (&gt;)25 kilogram per meter square (kg/m^2), initiated canagliflozin
        300 milligram (mg) as part of their treatment regimens, in real world clinical setting.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2DM participants on a stable anti-hyperglycemic regimen containing one or more
             anti-diabetic drug for at least 30 days and had HbA1c of more than 7 percent (%) at
             the time of, or within 2 weeks before canagliflozin 300 mg initiation

          -  T2DM participants as confirmed from hospital records

          -  T2DM participant having BMI&gt;25kg/m^2 at the time of canagliflozin 300 mg initiation

          -  Participants having clinical assessment data (at least glycated haemoglobin A1c
             [HbA1c] and body weight) for at least two visits, that is (i.e.) visit at which
             treatment with canagliflozin 300 mg was initiated or 2 weeks before initiation and
             follow-up visit at 12 weeks (+-4 weeks) from initiation, in accordance with the usual
             clinical practice

        Exclusion Criteria:

          -  Participants with history of autoimmune diabetes (type 1 diabetes mellitus [T1DM] or
             latent autoimmune diabetes in adults [LADA]), pancreas or beta-cell transplantation,
             or diabetes secondary to pancreatitis or pancreatectomy or gestational diabetes or any
             off-label use or patient data refusal based on physician discretion

          -  Participants with a history of use of other Sodium Glucose co-Transporter 2 (SGLT2)
             inhibitor within 12 weeks (empagliflozin or dapagliflozin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Private Limited Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Private Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diacon Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. A. Ramachandran's Diabetes Hospitals</name>
      <address>
        <city>Chennai</city>
        <zip>600032</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals</name>
      <address>
        <city>Kolkata</city>
        <zip>700054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

